HELICOBACTER PYLORI AND GASTRIC CANCER

本项目研究幽门螺杆菌（H.p.）胃 癌前病变 虽然一些关于这方面的信息 关系是由项目1产生的，它将被考虑，分析， 与特别是在该报告中获得的信息一起解释， 项目 项目1的工作将集中于 与H.p.相关的形态学参数， 长期治疗（long term treatment） 本项目将研究时间 幽门螺杆菌感染与组织学胃炎的关系 用特异性控制细菌感染的药物（铋， 甲硝唑和呋喃唑酮）vs仅具有细胞保护作用的药物 （硫糖铝）。 此外，病例对照研究将解决以下问题： 与胃炎类型相关的危险因素， 并发症（溃疡）。 研究将在新奥尔良进行 （慈善医院）和哥伦比亚，在胃癌高危人群中 癌 幽门螺杆菌的限制酶和对药物的敏感性将是 分析了

This project examines the role of Helicobacter pylori (H.p.) in the gastric precancerous process. Although some of the information on such relationship is generated by project 1, it will be considered, analyzed and interpreted together with the information obtained specifically in the project. The work conducted in project 1 will concentrate on the morphologic parameters associated with H.p. that are modified with prolonged treatment (long term). This project will examine the temporal relationship between H.p. infection and histologic gastritis by means of trials with drugs which specifically control bacterial infection (bismuth, metronidazol and furazolidone) vs drugs with only cytoprotective role (sucralfate). Additionally, a case control study will address the issue of risk factor specifically associated with the type of gastritis and the complications (ulcers). Studies will be carried out in New Orleans (Charity Hospital) and Colombia, in populations at high risk of gastric cancer. Restrictions enzymes of H.p. and sensitivity to drugs will be analyzed.